NGNE · Neurogene Inc.
$37.99
-1.44 (-3.65%)
At close · Aug 20
Market Cap
$789.05M
Shares
20.01M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$37.99
Open$38.55
Day$36.78–38.60
52W close$16.37–42.84
Avg vol 30d191K
Short int3.0M · 15.0% float · 16.2d
Short vol62%
Last earningsAug 11, 2025
DataDec 2023–Aug 2026
Filing10-Q · Aug 11
Raw chart and full-history price indicators begin at the captured split on Dec 19, 2023; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+49%
above
Price vs 50-day avg
+10%
above
RSI (14)
58
neutral
MACD trend
Positive
52-week position
82%
mid-range
Momentum
relative strength
1-month return
+7%
trailing
6-month return
+62%
trailing
YTD return
+84%
this year
Relative strength
+51%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $35 › 200d $26 — 50d above 200d
Institutional flow
Accumulating
+14% holders QoQ · +21 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.02% of float · ▲ +2.6% MoM · 16.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
112 holders — near 2-yr high, broad support
Squeeze score
87
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+1%
Y/Y
Free cash flow
$-78.4M
Balance sheet
$103.8M
net cash
Quant / Vol
risk profile
Volatility
83%
annualized · 1-yr
Max drawdown
−52%
past year
ATR
6.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+49%
Bullish
Price vs 50-day avg
+10%
Bullish
RSI (14)
58
Neutral
MACD trend
Positive
Bullish
52-week position
82%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $35 › 200d $26 — 50d above 200d
Institutional flow
Accumulating
+14% holders QoQ · +21 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.02% of float · ▲ +2.6% MoM · 16.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
112 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $16
Now $38 · 82%
Range high $43
vs 200-day avg +49%
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NGNE
this stock
Neurogene Inc.
|
$789.05M | +84.4% | -100.0% | — | 15.0% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Dec 19, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NGNE | +6.6% | +6.8% | +61.7% | +15.5% | +84.4% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +8.6% | +3.5% | +50.6% | +13.4% | +72.6% |